+ Watch TTHI
on My Watchlist
Because as the baby boomers grow older, the need for "alternative" medical therapy will grow with them. Therefore this stock will outperform.
I've done well with Transition, both in CAPS and real-life, but lost score leadership to one of those stochastic plays - i.e. with enough players randomly opening and ending picks someone will green thumb the stock at a deep bottom and close at the top. Of course, once they've closed the pick they're stuck with their score because they aren't likely to win the lottery twice. But I keep grinding away and eventually I'll take the top spot back.I made about $11000 on Transition in late April after the company reported encouraging data from their phase I proof of concept trial of GLP agonist peptide TT-401. Transition was definitely undervalued ahead of that catalyst and I would have loved to have green thumbed the stock and recorded my real life buy ahead of data, but CAPS had the stock as unratable. More and more of the best plays in biotech seem to be falling into that unratable hole, just another reason why Twitter is becoming a better place to track my performance.Lilly has picked up their option on TT-401 which will require them to assume the responsibility for development and commercialization of the drug, except for 14M in payments from Transition during an upcoming phase II trial. If TT-401 is successfully commercialized, Transition is eligible for up to 240M in milestones and double digit royalties. Phase II trials of ELND005 in bipolar disorder and Alzheimer's apparently continue to enroll but I have low expectations for positive outcomes. Nevertheless, Transition still seems undervalued at a cap of 83M given the Lilly partnership and the prospects for TT-401. Compare Lexicon and its billion dollar market cap for a novel diabetes drug (admittedly further in development) and a couple of less exciting compounds in clinical development. Transition remains a low volume and sparsely followed stock, which I have found to be the best opportunities in the sector.
zz pick, plus nice technical entry, long-term fantastic prospects for a 100% return, but will it take a week, month, or year? Time will tell
7.93 price/earnings, 1.95 price/book, debt/equity of zero, Return on Invested Capital (TTM) of 29.91, biopharmaceutical company based in Canada.
ELND-005 should get some clarity within the next few months. Go long here for the big gain.
ultralong plus recent chart...
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions